Abstract
Mosunetuzumab, a Novel CD20/CD3 Bispecific Antibody, in Combination with CHOP Confers High Response Rates in Patients with Diffuse Large B-Cell Lymphoma
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have